FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis.

Journal: JACC. Advances
Published Date: Dec 9, 2023

Abstract

BACKGROUND: In patients with chronic kidney disease (CKD), fibroblast growth factor (FGF)-23 is suspected to cause death or cardiovascular disease by inducing left ventricular hypertrophy (LVH).

Authors

  • Naoko Hidaka
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.
  • Kosuke Inoue
    Department of Social Epidemiology, Graduate School of Medicine, Kyoto University, Sakyo, Kyoto, Japan.
  • Hajime Kato
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.
  • Yoshitomo Hoshino
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.
  • Minae Koga
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.
  • Yuka Kinoshita
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.
  • Yuichi Takashi
    Department of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Jonan, Fukuoka, Japan.
  • Noriko Makita
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.
  • Seiji Fukumoto
    Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
  • Masaomi Nangaku
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.
  • Nobuaki Ito
    Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Bunkyo, Tokyo, Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals